Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07861542
PHASE4

Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19

Sponsor: Sanofi

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and immunogenicity of a single dose of Sanofi's Omicron subvariant-based Nuvaxovid in participants ≥ 65 years of age and participants 12 through 64 years of age who have at least one underlying condition that puts them at increased risk for severe outcomes of COVID-19 and who have been previously vaccinated with a COVID-19 vaccine ≥ 90 days prior to study vaccination. Study details include: * The study duration will be approximately 3 months per participant. * Study intervention will be administered via a single intramuscular (IM) injection into the deltoid muscle on Day 1. * The visit frequency will be Day 1, Day 9 telephone call, Day 29, and Day 91 telephone call (3-month safety follow-up).

Official title: A Phase 4 Open-label, Single-arm Study to Evaluate the Safety and Immunogenicity of an Omicron Subvariant-based SARS-CoV-2 Recombinant Spike (rS) Vaccine Adjuvanted With Matrix-M in Participants ≥ 65 Years of Age and Participants 12 Through 64 Years of Age Who Are at Increased Risk for Severe COVID-19 Illness

Key Details

Gender

All

Age Range

12 Years - Any

Study Type

INTERVENTIONAL

Enrollment

660

Start Date

2026-10-01

Completion Date

2027-01-27

Last Updated

2026-10-15

Healthy Volunteers

Yes

Conditions

Interventions

BIOLOGICAL

Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M

Pharmaceutical form: Sterile suspension for injection Route of administration: Intramuscular injection

Locations (20)

Site #: 8400005

Fair Oaks, California, United States

Site #: 8400002

Doral, Florida, United States

Site #: 8400008

Atlanta, Georgia, United States

Site #: 8400015

Decatur, Georgia, United States

Site #: 8400011

Melrose Park, Illinois, United States

Site #: 8400019

Sioux City, Iowa, United States

Site #: 8400009

Lenexa, Kansas, United States

Site #: 8400001

Lafayette, Louisiana, United States

Site #: 8400003

New Orleans, Louisiana, United States

Site #: 8400024

Rockville, Maryland, United States

Site #: 8400012

Southfield, Michigan, United States

Site #: 8400023

Grand Island, Nebraska, United States

Site #: 8400004

Omaha, Nebraska, United States

Site #: 8400021

Omaha, Nebraska, United States

Site #: 8400016

Cincinnati, Ohio, United States

Site #: 8400007

Philadelphia, Pennsylvania, United States

Site #: 8400018

Austin, Texas, United States

Site #: 8400017

Frisco, Texas, United States

Site #: 8400014

Houston, Texas, United States

Site #: 8400013

Richmond, Virginia, United States